[{"id":"5a1c0c02-4fea-4ff0-a201-7fca228602a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05283330","created_at":"2022-03-16T15:54:24.236Z","updated_at":"2024-07-02T16:35:32.524Z","phase":"Phase 1","brief_title":"Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors","source_id_and_acronym":"NCT05283330","lead_sponsor":"Orano Med LLC","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 212Pb-DOTAM-GRPR1"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 12/22/2022","start_date":" 12/22/2022","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2023-10-19"}]